Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates […]
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Ardelyx’s $20 Million Agreement with HealthCare Royalty Partners
Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop […]
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq: […]
Alborz’s $46.9 Million Secured Credit Facility
Latham & Watkins advised Cipher Mining in the transaction. Alborz LLC, a joint venture affiliate of Cipher Mining Inc. (NASDAQ: CIFR) and WindHQ LLC, has announced […]
SatixFy’s $813 Million Combination With Endurance Acquisition
Davis Polk and Gross & Co. advised SatixFy Communications Ltd. on the deal. Appleby and Morrison & Foerster acted for Endurance Acquisition Corp. Latham & Watkins […]
Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed […]
Atmosphere’s $100 Million Funding
Latham & Watkins represented Atmosphere in the transaction. Atmosphere, the worldwide leader in streaming TV entertainment for businesses, has announced a new US$80 million Series C […]
Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has […]